# The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

> **NCT01813214** · PHASE2 · TERMINATED · sponsor: **Georgetown University** · enrollment: 5 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Vemurafenib
- **DRUG:** Cobimetinib

## Key facts

- **NCT ID:** NCT01813214
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03
- **Primary completion:** 2016-08
- **Final completion:** 2016-12
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Recruitment difficulties.
- **Last updated:** 2019-02-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813214, "The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01813214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*